Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ileitis Clear all
Recruiting Early Phase 1 Interventional

Fecal Microbiota Transplant for Patients With Chronic Pouchitis

NCT05829109
View directory record Official record
Conditions
Chronic Pouchitis, Pouchitis
Interventions
Fecal Microbiota Transplant (FMT)
Drug
Lead sponsor
Maia Kayal
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Jul 22, 2026, 10:24 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis

NCT02790138
View directory record Official record
Conditions
Pouchitis
Interventions
Vedolizumab Placebo, Ciprofloxacin, Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Chicago, Illinois • Evanston, Illinois • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Jul 22, 2026, 10:24 AM EDT
Terminated Phase 2Phase 3 Interventional

The Role of Secondary Bile Acids in Intestinal Inflammation

NCT03724175
View directory record Official record
Conditions
Ulcerative Colitis, Pouchitis
Interventions
ursodiol (ursodeoxycholic acid, UDCA)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jul 22, 2026, 10:24 AM EDT
Withdrawn Phase 1 Interventional

Stem Cells for the Treatment of Pouchitis

NCT05578508
View directory record Official record
Conditions
Pouchitis, Crohn's Disease, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Pouch, Ileal
Interventions
Mesenchymal Stem Cells (MSCs)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 22, 2026, 10:24 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP)

NCT02782325
View directory record Official record
Conditions
Pouchitis
Interventions
Active FMT, then open label FMT, Placebo FMT, then open label FMT
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Jul 22, 2026, 10:24 AM EDT
Recruiting Phase 4 Interventional

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

NCT06864403
View directory record Official record
Conditions
Pouchitis, Pouches, Ileoanal, Pouch, Ileal
Interventions
Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jul 22, 2026, 10:24 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis

NCT00583531
View directory record Official record
Conditions
Pouchitis
Interventions
AST-120
Drug
Lead sponsor
Ocera Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Jul 22, 2026, 10:24 AM EDT
Recruiting Phase 4 Interventional

Rifaximin for the Secondary Prevention of Recurrent Pouchitis

NCT06312683
View directory record Official record
Conditions
Pouchitis
Interventions
Rifaximin 550 MG Oral Tablet [XIFAXAN]
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 74 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jul 22, 2026, 10:24 AM EDT
Completed Phase 1 Interventional

Study of Sc-FOS for Pouchitis Prevention

NCT02203955
View directory record Official record
Conditions
Pouchitis
Interventions
Short-Chain Fructooligosaccharide, Maltodextrin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Jul 22, 2026, 10:24 AM EDT
Completed Phase 2 Interventional

Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis

NCT04741087
View directory record Official record
Conditions
Pouchitis
Interventions
AMT-101 (oral)-Dose A, AMT-101 (oral)-Dose B
Drug
Lead sponsor
Applied Molecular Transport
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Bristol, Connecticut • Chicago, Illinois • Chevy Chase, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Jul 22, 2026, 10:24 AM EDT
Terminated Phase 2 Interventional Results available

Tofacitinib For Treatment Of Chronic Pouchitis

NCT04580277
View directory record Official record
Conditions
Pouchitis, Ileal Pouchitis, Ileal Pouch
Interventions
Tofacitinib 10 mg
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Jul 22, 2026, 10:24 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Liraglutide Therapy in Patients With IPAA

NCT04763564
View directory record Official record
Conditions
Pouchitis, Irritable Pouch Syndrome
Interventions
Liraglutide Pen Injector, Placebo Pen Injector
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Jul 22, 2026, 10:24 AM EDT
Completed Not applicable Interventional

Nutritional Impact of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With IPAA

NCT02828410
View directory record Official record
Conditions
Pouchitis, Irritable Pouch Syndrome
Interventions
SBI
Dietary Supplement
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Jul 22, 2026, 10:24 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Treating Chronic Pouchitis With a Low FODMAP Diet

NCT04640155
View directory record Official record
Conditions
Pouchitis
Interventions
Low FODMAP Diet, Regular Diet
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Jul 22, 2026, 10:24 AM EDT
Completed Early Phase 1 Interventional

Fecal Microbiota Transplant (FMT) for Pouchitis

NCT02428361
View directory record Official record
Conditions
Pouchitis
Interventions
Biologically active human fecal material, OpenBiome
Drug
Lead sponsor
Najwa Elnachef
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Jul 22, 2026, 10:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics

NCT02525523
View directory record Official record
Conditions
Pouchitis
Interventions
Alicaforsen, Placebo
Drug
Lead sponsor
Atlantic Pharmaceuticals Ltd
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Jul 22, 2026, 10:24 AM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Crohn's Disease

NCT04100005
View directory record Official record
Conditions
Crohn Disease, Crohn Colitis, Crohn's Ileocolitis, Crohn Ileitis, Crohn Disease of Ileum, Crohn's Disease Relapse, Crohn's Gastritis, Crohns Disease Aggravated, Crohn Disease in Remission, Crohn's Jejunitis, Crohn's Duodenitis, Crohn's Disease of Pylorus, Crohn's Esophagitis, Crohn's
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jul 22, 2026, 10:24 AM EDT
Suspended Phase 2 Interventional

CLF065 for Chronic Pouchitis

NCT07226050
View directory record Official record
Conditions
Pouchitis
Interventions
CLF065, Placebo
Drug
Lead sponsor
Calibr, a division of Scripps Research
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
La Jolla, California • Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 10:24 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of AST-120 in the Treatment of Pouchitis

NCT00583076
View directory record Official record
Conditions
Pouchitis
Interventions
AST-120
Drug
Lead sponsor
Ocera Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Jul 22, 2026, 10:24 AM EDT
Recruiting Phase 2 Interventional

Etrasimod as Prevention of Pouchitis

NCT07486921
View directory record Official record
Conditions
Pouchitis
Interventions
etrasimod, Placebo
Drug
Lead sponsor
Maia Kayal
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 10:24 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)

NCT05938465
View directory record Official record
Conditions
Ileal Pouch
Interventions
EXE-346, Placebo
Biological · Other
Lead sponsor
Exegi Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Los Angeles, California • Jacksonville, Florida • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 22, 2026, 10:24 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Clotrimazole Enemas for Pouchitis in Children and Adults

NCT00061282
View directory record Official record
Conditions
Ulcerative Colitis, Pouchitis, Ileitis, Inflammatory Bowel Disease
Interventions
Clotrimazole
Drug
Lead sponsor
Web
Other
Eligibility
2 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Jul 22, 2026, 10:24 AM EDT
Suspended No phase listed Observational

Assessment of Patients With Acute Pouchitis Treated With Antibiotics

NCT05252273
View directory record Official record
Conditions
Pouchitis, Ulcerative Colitis
Interventions
Observational, No intervention
Other
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Jul 22, 2026, 10:24 AM EDT
Completed Phase 3 Interventional

Clinical Approaches to Ileal Pouch Dysfunction

NCT00293553
View directory record Official record
Conditions
Pouchitis
Interventions
Electronic Barostat
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Jul 22, 2026, 10:24 AM EDT